KBC Group NV reduced its stake in shares of Mednax, Inc (NYSE:MD) by 74.3% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 12,335 shares of the company’s stock after selling 35,671 shares during the quarter. KBC Group NV’s holdings in Mednax were worth $532,000 as of its most recent filing with the SEC.

Several other large investors also recently made changes to their positions in MD. Fuller & Thaler Asset Management Inc. purchased a new stake in Mednax during the 3rd quarter worth approximately $103,000. Pacer Advisors Inc. increased its holdings in Mednax by 8.1% during the 2nd quarter. Pacer Advisors Inc. now owns 1,940 shares of the company’s stock worth $117,000 after purchasing an additional 145 shares during the last quarter. Commonwealth Bank of Australia increased its holdings in Mednax by 15.3% during the 2nd quarter. Commonwealth Bank of Australia now owns 2,205 shares of the company’s stock worth $132,000 after purchasing an additional 293 shares during the last quarter. Daiwa Securities Group Inc. increased its holdings in Mednax by 20.0% during the 2nd quarter. Daiwa Securities Group Inc. now owns 3,000 shares of the company’s stock worth $181,000 after purchasing an additional 500 shares during the last quarter. Finally, Denali Advisors LLC purchased a new stake in Mednax during the 3rd quarter worth approximately $185,000. Institutional investors and hedge funds own 98.48% of the company’s stock.

Mednax, Inc (NYSE MD) opened at $51.10 on Friday. Mednax, Inc has a 12-month low of $40.56 and a 12-month high of $72.13. The stock has a market capitalization of $4,790.00, a P/E ratio of 15.63, a P/E/G ratio of 1.65 and a beta of 0.40. The company has a debt-to-equity ratio of 0.62, a quick ratio of 1.37 and a current ratio of 1.37.

Mednax (NYSE:MD) last released its quarterly earnings data on Wednesday, November 1st. The company reported $0.87 earnings per share (EPS) for the quarter, meeting the Zacks’ consensus estimate of $0.87. Mednax had a return on equity of 10.80% and a net margin of 7.76%. The business had revenue of $868.95 million during the quarter, compared to analyst estimates of $864.78 million. During the same quarter in the previous year, the firm posted $1.09 EPS. The business’s revenue for the quarter was up 4.9% compared to the same quarter last year. equities analysts forecast that Mednax, Inc will post 3.1 earnings per share for the current fiscal year.

In related news, insider John C. Pepia sold 3,000 shares of the business’s stock in a transaction that occurred on Tuesday, December 12th. The stock was sold at an average price of $51.58, for a total transaction of $154,740.00. Following the completion of the transaction, the insider now owns 35,569 shares in the company, valued at approximately $1,834,649.02. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Cesar L. Alvarez sold 10,668 shares of the business’s stock in a transaction that occurred on Friday, November 3rd. The shares were sold at an average price of $42.59, for a total value of $454,350.12. Following the transaction, the director now owns 44,215 shares of the company’s stock, valued at approximately $1,883,116.85. The disclosure for this sale can be found here. Insiders own 2.40% of the company’s stock.

MD has been the subject of several research reports. Robert W. Baird reiterated a “hold” rating and issued a $47.00 target price on shares of Mednax in a research report on Sunday, September 3rd. Zacks Investment Research upgraded Mednax from a “sell” rating to a “hold” rating in a research report on Wednesday, October 11th. Piper Jaffray Companies initiated coverage on Mednax in a research report on Wednesday. They issued an “overweight” rating and a $58.00 target price for the company. KeyCorp set a $51.00 target price on Mednax and gave the stock a “buy” rating in a research report on Wednesday, November 1st. Finally, BMO Capital Markets initiated coverage on Mednax in a research report on Monday, October 16th. They issued a “market perform” rating and a $46.00 target price for the company. Two equities research analysts have rated the stock with a sell rating, nine have given a hold rating and three have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus target price of $53.70.

COPYRIGHT VIOLATION WARNING: “KBC Group NV Has $532,000 Position in Mednax, Inc (MD)” was reported by Watch List News and is the sole property of of Watch List News. If you are accessing this piece on another website, it was stolen and reposted in violation of U.S. and international copyright and trademark legislation. The original version of this piece can be viewed at https://www.watchlistnews.com/kbc-group-nv-has-532000-position-in-mednax-inc-md/1767899.html.

About Mednax

MEDNAX, Inc is a provider of physician services, including newborn, anesthesia, maternal-fetal, teleradiology, pediatric cardiology and other pediatric subspecialty care. As of December 31, 2016, the Company’s national network consisted of over 3,600 affiliated physicians, including over 1,130 physicians providing neonatal clinical care, in 35 states and Puerto Rico, primarily within hospital-based neonatal intensive care units (NICUs), to babies born prematurely or with medical complications.

Want to see what other hedge funds are holding MD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Mednax, Inc (NYSE:MD).

Institutional Ownership by Quarter for Mednax (NYSE:MD)

Receive News & Ratings for Mednax Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mednax and related companies with MarketBeat.com's FREE daily email newsletter.